Use of ultrasmall superparamagnetic iron oxide particles for imaging carotid atherosclerosis

Nanomedicine

Volumn 10, Issue 19, 2015, Pages 3077-3087

  Usman, Ammara ^a   Sadat, Umar ^b   Patterson, Andrew J ^a   Tang, Tjun Y ^c   Varty, Kevin ^b   Boyle, Jonathan R ^b   Armon, Mathew P ^d   Hayes, Paul D ^b   Graves, Martin J ^a   Gillard, Jonathan H ^a  

^a ADDENBROOKE S HOSPITAL   (United Kingdom)

^b CAMBRIDGE UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^c CHANGI GENERAL HOSPITAL   (Singapore)

^d NORFOLK AND NORWICH UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

atherosclerosis; cellular imaging; ferumoxtran 10; ferumoxytol; inflammation; iron oxide; MRI; nanoparticle; USPIO

Indexed keywords

FERUMOXYTOL; NUCLEAR MAGNETIC RESONANCE IMAGING AGENT; ULTRASMALL SUPERPARAMAGNETIC IRON OXIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; CAROTID ATHEROSCLEROSIS; CHEMICAL COMPOSITION; CLINICAL STUDY; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG METABOLISM; DRUG UPTAKE; MACROPHAGE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PHARMACOKINETICS; PLASMA HALF LIFE; PRIORITY JOURNAL; RABBIT MODEL; RADIODIAGNOSIS; REVIEW;

EID: 84944212676     PISSN: 17435889     EISSN: 17486963     Source Type: Journal    
DOI: 10.2217/nnm.15.136     Document Type: Review

References (68)

1. Lozano R, Naghavi M, Foreman K et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 380(9859), 2095-2128 (2012).
2. Vos T, Flaxman AD, Naghavi M et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 380(9859), 2163-2196 (2012).
3. Mant J, Wade DT, Winner S. Health care needs assessment: stroke. In: Health Care Needs Assessment: The Epidemiologically Based Needs Assessment Reviews, First Series (2nd Edition). Stevens A, Raftery J, Mant J (Eds). Radcliffe Medical Press, Oxford, UK, 141-244 (2004).
4. Libby P, Lichtman AH, Hansson GK. Immune effector mechanisms implicated in atherosclerosis: from mice to humans. Immunity 38(6), 1092-1104 (2013).
5. Chinetti-Gbaguidi G, Colin S, Staels B. Macrophage subsets in atherosclerosis. Nat. Rev. Cardiol. 12(1), 10-17 (2015).
6. Libby P. Inflammation and cardiovascular disease mechanisms. Am. J. Clin. Nutr. 83(2), 456S-460S (2006).
7. Falk E, Nakano M, Bentzon JF, Finn AV, Virmani R. Update on acute coronary syndromes: the pathologists' view. Eur. Heart J. 34(10), 719-728 (2013).
8. Ruehm SG, Corot C, Vogt P, Kolb S, Debatin JF. Magnetic resonance imaging of atherosclerotic plaque with ultrasmall superparamagnetic particles of iron oxide in hyperlipidemic rabbits. Circulation 103(3), 415-422 (2001).
9. Kooi ME, Cappendijk VC, Cleutjens KB et al. Accumulation of ultrasmall superparamagnetic particles of iron oxide in human atherosclerotic plaques can be detected by in vivo magnetic resonance imaging. Circulation 107(19), 2453-2458 (2003).
10. Trivedi RA, JM UK-I, Graves MJ et al. In vivo detection of macrophages in human carotid atheroma: temporal dependence of ultrasmall superparamagnetic particles of iron oxide-enhanced MRI. Stroke 35(7), 1631-1635 (2004).
11. Hyafil F, Laissy JP, Mazighi M et al. Ferumoxtran-10-enhanced MRI of the hypercholesterolemic rabbit aorta: relationship between signal loss and macrophage infiltration. Arterioscler. Thromb. Vasc. Biol. 26(1), 176-181 (2006).
12. Tang TY, Howarth SP, Miller SR et al. The ATHEROMA (Atorvastatin Therapy: Effects on Reduction of Macrophage Activity) Study. Evaluation using ultrasmall superparamagnetic iron oxide-enhanced magnetic resonance imaging in carotid disease. J. Am. Coll. Cardiol. 53(22), 2039-2050 (2009).
13. Di Marco M, Sadun C, Port M et al. Physicochemical characterization of ultrasmall superparamagnetic iron oxide particles (USPIO) for biomedical application as MRI contrast agents. Int. J. Nanomedicine 2(4), 609-622 (2007).
14. Jefferson A, Wijesurendra RS, McAteer MA, Choudhury RP. Development and application of endothelium-targeted microparticles for molecular magnetic resonance imaging. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 4(3), 247-256 (2012).
15. Williams JB, Ye Q, Hitchens TK, Kaufman CL, Ho C. MRI detection of macrophages labeled using micrometersized iron oxide particles. J. Magn. Reson. Imaging 25(6), 1210-1218 (2007).
16. Corot C, Robert P, Idee JM, Port M. Recent advances in iron oxide nanocrystal technology for medical imaging. Adv. Drug Deliv. Rev. 58(14), 1471-1504 (2006).
17. Bonnemain B. Superparamagnetic agents in magnetic resonance imaging: physicochemical characteristics and clinical applications. A review. J. Drug Target. 6(3), 167-174 (1998).
18. Leenders W. Ferumoxtran-10 advanced magnetics. IDrugs 6(10), 987-993 (2003).
19. Fleige G, Seeberger F, Laux D et al. In vitro characterization of two different ultrasmall iron oxide particles for magnetic resonance cell tracking. Invest. Radiol. 37(9), 482-488 (2002).
20. Wagner S, Schnorr J, Pilgrimm H, Hamm B, Taupitz M. Monomer-coated very small superparamagnetic iron oxide particles as contrast medium for magnetic resonance imaging: preclinical in vivo characterization. Invest. Radiol. 37(4), 167-177 (2002).
21. Bjornerud A, Johansson LO, Ahlstrom HK. Pre-clinical results with Clariscan (NC100150 Injection): experience from different disease models. Magma. 12(2-3), 99-103 (2001).
22. Skotland T, Sontum PC, Oulie I. In vitro stability analyses as a model for metabolism of ferromagnetic particles (Clariscan), a contrast agent for magnetic resonance imaging. J. Pharmaceut. Biomed. Anal. 28(2), 323-329 (2002).
23. Kellar KE, Fujii DK, Gunther WH et al. 'NC100150', a preparation of iron oxide nanoparticles ideal for positivecontrast MR angiography. Magma. 8(3), 207-213 (1999).
24. Tombach B, Reimer P, Mahler M et al. First-pass and equilibrium phase MRA following intravenous bolus injection of SH U 555 C: Phase I clinical trial in elderly volunteers with risk factors for arterial vascular disease. Acad. Radiol. 9(Suppl. 2), S425-S427 (2002).
25. Muhler A, Zhang X, Wang H, Lawaczeck R, Weinmann HJ. Investigation of mechanisms influencing the accumulation of ultrasmall superparamagnetic iron oxide particles in lymph nodes. Invest. Radiol. 30(2), 98-103 (1995).
26. Weissleder R, Bogdanov A, Papisov M. Drug targeting in magnetic resonance imaging. Magn. Reson. Q 8(1), 55-63 (1992).
27. Moore A, Weissleder R, Bogdanov A Jr. Uptake of dextrancoated monocrystalline iron oxides in tumor cells and macrophages. J. Magn. Reson. Imaging 7(6), 1140-1145 (1997).
28. Wilhelm C, Billotey C, Roger J et al. Intracellular uptake of anionic superparamagnetic nanoparticles as a function of their surface coating. Biomaterials 24(6), 1001-1011 (2003).
29. Arbab AS, Bashaw LA, Miller BR et al. Intracytoplasmic tagging of cells with ferumoxides and transfection agent for cellular magnetic resonance imaging after cell transplantation: methods and techniques. Transplantation 76(7), 1123-1130 (2003).
30. Metz S, Bonaterra G, Rudelius M et al. Capacity of human monocytes to phagocytose approved iron oxide MR contrast agents in vitro. Eur. Radiol. 14(10), 1851-1858 (2004).
31. Raynal I, Prigent P, Peyramaure S et al. Macrophage endocytosis of superparamagnetic iron oxide nanoparticles: mechanisms and comparison of ferumoxides and ferumoxtran-10. Invest. Radiol. 39(1), 56-63 (2004).
32. Pratten MK, Lloyd JB. Pinocytosis and phagocytosis: the effect of size of a particulate substrate on its mode of capture by rat peritoneal macrophages cultured in vitro. Biochim. Biophys. Acta 881(3), 307-313 (1986).
33. von Zur Muhlen C, von Elverfeldt D, Bassler N et al. Superparamagnetic iron oxide binding and uptake as imaged by magnetic resonance is mediated by the integrin receptor Mac-1 (CD11b/CD18): implications on imaging of atherosclerotic plaques. Atherosclerosis 193(1), 102-111 (2007).
34. Muller K, Skepper JN, Posfai M et al. Effect of ultrasmall superparamagnetic iron oxide nanoparticles (Ferumoxtran-10) on human monocyte-macrophages in vitro. Biomaterials 28(9), 1629-1642 (2007).
35. McLachlan SJ, Morris MR, Lucas MA et al. Phase I clinical evaluation of a new iron oxide MR contrast agent. J. Magn. Reson. Imaging 4(3), 301-307 (1994).
36. Food and Drug Administration Agency (FDA). Feraheme. FDA/AMAG Pharmaceuticals, Inc (2009). www. accessdata. fda. gov/drugsatfda-docs
37. Sadat U, Taviani V, Patterson AJ et al. Ultrasmall superparamagnetic iron oxide-enhanced magnetic resonance imaging of abdominal aortic aneurysms-a feasibility study. Eur. J. Vasc. Endovasc. Surg. 41(2), 167-174 (2011).
38. CHMP. Committee for Medicinal Products for Human Use Assessment Report (Rienso™ Ferumoxytol). Europeon Medical Agency, UK (2012). www. ema. europa. eu/docs/en-GB/document-library
39. Kalber TL, Smith CJ, Howe FA et al. A longitudinal study of R2 and R2 magnetic resonance imaging relaxation rate measurements in murine liver after a single administration of 3 different iron oxide-based contrast agents. Invest. Radiol. 40(12), 784-791 (2005).
40. Weissleder R, Cheng HC, Bogdanova A, Bogdanov A Jr. Magnetically labeled cells can be detected by MR imaging. J. Magn. Reson. Imaging 7(1), 258-263 (1997).
41. Majumdar S, Zoghbi SS, Gore JC. Pharmacokinetics of superparamagnetic iron-oxide MR contrast agents in the rat. Invest. Radiol. 25(7), 771-777 (1990).
42. Anastase S, Letourneur D, Jozefonvicz J. Affinity chromatography of human anti-dextran antibodies. Isolation of two distinct populations. J. Chromatogr. B 686(2), 141-150 (1996).
43. Fishbane S, Ungureanu VD, Maesaka JK et al. The safety of intravenous iron dextran in hemodialysis patients. Am. J. Kidney Dis. 28(4), 529-534 (1996).
44. Zinderman CE, Landow L, Wise RP. Anaphylactoid reactions to Dextran 40 and 70: reports to the United States Food and Drug Administration, 1969 to 2004. J. Vasc. Surg. 43(5), 1004-1009 (2006).
45. Szebeni J. Complement activation-related pseudoallergy: a new class of drug-induced acute immune toxicity. Toxicology 216(2-3), 106-121 (2005).
46. Yancy AD, Olzinski AR, Hu TC et al. Differential uptake of ferumoxtran-10 and ferumoxytol, ultrasmall superparamagnetic iron oxide contrast agents in rabbit: critical determinants of atherosclerotic plaque labeling. J. Magn. Reson. Imaging 21(4), 432-442 (2005).
47. Hasan DM, Mahaney KB, Magnotta VA et al. Macrophage imaging within human cerebral aneurysms wall using ferumoxytol-enhanced MRI: a pilot study. Arterioscler. Thromb. Vasc. Biol. 32(4), 1032-1038 (2012).
48. Hasan D, Chalouhi N, Jabbour P et al. Early change in ferumoxytol-enhanced magnetic resonance imaging signal suggests unstable human cerebral aneurysm: a pilot study. Stroke 43(12), 3258-3265 (2012).
49. Moreno PR, Falk E, Palacios IF et al. Macrophage infiltration in acute coronary syndromes. Implications for plaque rupture. Circulation 90(2), 775-778 (1994).
50. Tang TY, Muller KH, Graves MJ et al. Iron oxide particles for atheroma imaging. Arterioscler Thromb. Vasc. Biol. 29(7), 1001-1008 (2009).
51. Trivedi RA, Mallawarachi C, JM UK-I et al. Identifying inflamed carotid plaques using in vivo USPIO-enhanced MR imaging to label plaque macrophages. Arterioscler. Thromb. Vasc. Biol. 26(7), 1601-1606 (2006).
52. Tang TY, Howarth SP, Miller SR et al. Comparison of the inflammatory burden of truly asymptomatic carotid atheroma with atherosclerotic plaques contralateral to symptomatic carotid stenosis: an ultra small superparamagnetic iron oxide enhanced magnetic resonance study. J. Neurol. Neurosurg. Psychiatr. 78(12), 1337-1343 (2007).
53. Tang TY, Howarth SP, Miller SR et al. Comparison of the inflammatory burden of truly asymptomatic carotid atheroma with atherosclerotic plaques in patients with asymptomatic carotid stenosis undergoing coronary artery bypass grafting: an ultrasmall superparamagnetic iron oxide enhanced magnetic resonance study. Eur. J. Vasc. Endovasc. Surg. 35(4), 392-398 (2008).
54. Tang TY, Howarth SP, Miller SR et al. Correlation of carotid atheromatous plaque inflammation using USPIO-enhanced MR imaging with degree of luminal stenosis. Stroke 39(7), 2144-2147 (2008).
55. Fayad ZA, Razzouk L, Briley-Saebo KC, Mani V. Iron oxide magnetic resonance imaging for atherosclerosis therapeutic evaluation: still "rusty". J. Am. Coll. Cardiol. 53(22), 2051-2052 (2009).
56. Tang T, Howarth SP, Miller SR et al. Assessment of inflammatory burden contralateral to the symptomatic carotid stenosis using high-resolution ultrasmall, superparamagnetic iron oxide-enhanced MRI. Stroke 37(9), 2266-2270 (2006).
57. Howarth SP, Tang TY, Trivedi R et al. Utility of USPIOenhanced MR imaging to identify inflammation and the fibrous cap: a comparison of symptomatic and asymptomatic individuals. Eur. J. Radiol. 70(3), 555-560 (2009).
58. Patterson AJ, Tang TY, Graves MJ, Muller KH, Gillard JH. In vivo carotid plaque MRI using quantitative T2 measurements with ultrasmall superparamagnetic iron oxide particles: a dose-response study to statin therapy. NMR Biomed. 24(1), 89-95 (2011).
59. Howarth SP, Li ZY, Tang TY et al. In vivo positive contrast IRON sequence and quantitative T(2) measurement confirms inflammatory burden in a patient with asymptomatic carotid atheroma after USPIO-enhanced MR imaging. J. Vasc. Interv. Radiol. 19(3), 446-448 (2008).
60. Diwoky C, Liebmann D, Neumayer B et al. Positive contrast of SPIO-labeled cells by off-resonant reconstruction of 3D radial half-echo bSSFP. NMR Biomed. 28(1), 79-88 (2015).
61. Wang L, Zhong X, Qian W et al. Ultrashort echo time (UTE) imaging of receptor targeted magnetic iron oxide nanoparticles in mouse tumor models. J. Magn. Reson. Imaging 40(5), 1071-1081 (2014).
62. Stadler N, Lindner RA, Davies MJ. Direct detection and quantification of transition metal ions in human atherosclerotic plaques: evidence for the presence of elevated levels of iron and copper. Arterioscler. Thromb. Vasc. Biol. 24(5), 949-954 (2004).
63. EMA. Europeon Medical Agency Withdrawal Assessment Report for Sinerem: European Medicines Agency preauthorisation evaluation of medicines for human use (21 February 2008). www. ema. europa. eu/docs/en-GB/document-library/
64. Lu M, Cohen MH, Rieves D, Pazdur R. FDA report: ferumoxytol for intravenous iron therapy in adult patients with chronic kidney disease. Am. J. Hematol. 85(5), 315-319 (2010).
65. Takeda. Rienso® (ferumoxytol) receives European marketing authorisation for the treatment of iron deficiency anaemia in adult chronic kidney disease patients. Takeda, London, UK (2012). www. takeda. com/news/2012/20120625-3975. html
66. Medicines & Healthcare Products Regulatory Agency. Ferumoxytol: risk of serious hypersensitivity reactions-contraindicated if any drug allergy; administer via infusion. Drug Saf. Update 8(2), 1-2 (2014).
67. Dosa E, Tuladhar S, Muldoon LL et al. MRI using ferumoxytol improves the visualization of central nervous system vascular malformations. Stroke 42(6), 1581-1588 (2011).
68. Neuwelt EA, Varallyay CG, Manninger S et al. The potential of ferumoxytol nanoparticle magnetic resonance imaging, perfusion, and angiography in central nervous system malignancy: a pilot study. Neurosurgery 60(4), 601-611; discussion 2-11 (2007).